Related Experiment Videos
IDN5109, a taxane with oral bioavailability and potent antitumor activity
M I Nicoletti1, T Colombo, C Rossi
1Department of Oncology, Laboratory of Biology and Treatment of Metastasis, Mario Negri Institute for Pharmacological Research, Bergamo, Italy. Nicoletti@irfmn.mnegri.it
Abstract:
IDN5109 is a new taxane, derived from 14beta-hydroxy-10-deacetylbaccatin III, selected for its lack of cross-resistance in tumor cell lines expressing the multidrug resistant phenotype. Because, unlike paclitaxel, IDN5109 is a poor substrate for P-glycoprotein, we hypothesized that IDN5109 given p.o. could improve bioavailability compared with paclitaxel. Here, we studied the p.o. and i.v. pharmacokinetics of IDN5109 together with its antitumor activity. Using a high-performance liquid chromatography method, the bioavailability of IDN5109 was determined to be 48% after oral delivery. IDN5109 given p.o. was highly active against the two human ovarian carcinoma xenografts 1A9 and HOC18 (90-100% tumor regressions) and showed significant activity on the paclitaxel-resistant MNB-PTX1 xenograft (10% tumor regressions). The p.o. administration was as active as the i.v. route at doses reflecting the pharmacokinetic data. IDN5109 is the first taxane with good oral bioavailability and potent antitumor activity and represents a potential candidate for clinical investigation.
Insights
IDN5109, a novel taxane, demonstrates significant oral bioavailability and potent antitumor activity. This new drug overcomes multidrug resistance, offering a promising oral cancer treatment candidate.
Area of Science:
- Pharmacology
- Oncology
- Drug Discovery
Background:
- Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
- Taxanes like paclitaxel are effective but face MDR and limited oral bioavailability.
- IDN5109 is a novel taxane derivative designed to overcome these limitations.
Purpose of the Study:
- To evaluate the oral and intravenous pharmacokinetics of IDN5109.
- To assess the antitumor activity of orally administered IDN5109 against various xenografts.
- To determine if IDN5109 exhibits reduced susceptibility to P-glycoprotein-mediated efflux.
Main Methods:
- Pharmacokinetic studies of IDN5109 via oral (p.o.) and intravenous (i.v.) routes.
- Antitumor efficacy assessment using human ovarian carcinoma xenografts (1A9, HOC18) and a paclitaxel-resistant xenograft (MNB-PTX1).
- High-performance liquid chromatography (HPLC) used for bioavailability determination.
Main Results:
- IDN5109 achieved 48% oral bioavailability.
- Oral IDN5109 demonstrated high efficacy (90-100% tumor regressions) against 1A9 and HOC18 xenografts.
- Significant activity (10% tumor regressions) was observed against the paclitaxel-resistant MNB-PTX1 xenograft.
- Oral administration showed comparable activity to i.v. administration at relevant doses.
Conclusions:
- IDN5109 is the first taxane with substantial oral bioavailability and potent antitumor effects.
- Its ability to bypass P-glycoprotein-mediated resistance makes it a promising candidate for oral cancer therapy.
- IDN5109 warrants further clinical investigation as a novel chemotherapeutic agent.